• In early January 2026, Xeris Biopharma Holdings, Inc. raised its full-year 2025 revenue guidance to approximately US$292 million, above its prior US$285–US$290 million range, signaling better-than-planned top-line performance.
• This upward revision suggests the company’s commercial portfolio is gaining more traction than initially forecast, reshaping how investors may assess its revenue potential and operational progress.
• We’ll now examine how this higher 2025 revenue guidance intersects with Xeris Biopharma’s existing growth narrative and analysts’ forward-looking assumptions.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Xeris Biopharma Holdings Investment Narrative Recap

To own Xeris Biopharma, you need to believe its focused endocrine and neurological portfolio can scale fast enough to overcome ongoing losses and balance sheet pressure. The higher 2025 revenue guidance to about US$292 million supports the near term revenue story, but it does not remove the key risk of heavy reliance on just a few products and the potential impact of new competitors or pricing pressure.

Among recent updates, the upcoming 2025 results release and XP-8121 and Recorlev analyst day in May 2025 stand out as closely linked to this upgraded guidance, because they frame how management presents the current portfolio trajectory alongside future pipeline potential. For investors, these events sit at the intersection of the near term revenue catalyst and the longer term uncertainty around funding and executing the next phase of growth.

Yet even with raised guidance, investors should be aware of how concentrated the revenue base remains and how...

Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from -$32.0 million today.

Uncover how Xeris Biopharma Holdings' forecasts yield a $11.50 fair value, a 53% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community see fair value anywhere between US$4.69 and about US$41.67 per share, underscoring very different expectations. Against that backdrop, the upgraded 2025 revenue guidance highlights how much views on Xeris’s concentrated portfolio and its ability to sustain growth can diverge, so it makes sense to compare several perspectives before forming your own.

Explore 4 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth over 5x more than the current price!

Build Your Own Xeris Biopharma Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.